MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral

MHRA-100805-PIP01-22-M01

Scope of the Application

Active Substance(s)

ATIDARSAGENE AUTOTEMCEL

Condition(s)

Treatment of metachromatic leukodystrophy (MLD)

Pharmaceutical Form(s)

Dispersion for infusion

Route(s) of Administration

INTRAVENOUS USE

Name / Corporate name of the PIP applicant

Orchard Therapeutics (Europe) Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Orchard Therapeutics (Europe) Limited submitted to the licensing authority on 09/12/2022 11:42 GMT an application for a Modification

The procedure started on 13/03/2023 17:39 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100805-PIP01-22-M01

Of 24/03/2023 11:54 GMT

On the adopted decision for ATIDARSAGENE AUTOTEMCEL (MHRA-100805-PIP01-22-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for ATIDARSAGENE AUTOTEMCEL, Dispersion for infusion , INTRAVENOUS USE .

This decision is addressed to Orchard Therapeutics (Europe) Limited, 245 Hammersmith Road, London, UNITED KINGDOM, W6 8PW

ANNEX I

1. Waiver

1.1 Condition:

Not applicable.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of metachromatic leukodystrophy (MLD)

2.2 Indication(s) targeted by the PIP:

Treatment of presymptomatic Late Infantile (LI), and presymptomatic or early symptomatic Early Juvenile (EJ) and Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD)

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from birth to less than 18 years of age

2.4 Pharmaceutical Form(s):

Dispersion for infusion

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 Development of a cryopreserved dispersion for infusion formulation.
Non-Clinical Studies	1	Study 2 Study in As2-/- mice transplanted with bone marrow Lin- transduced with arylsulfatase A (ARSA) LV (GSK3485860 2) the murine equivalent of GSK2696274), to investigate the potential toxicity and tumorigenicity of GSK2696274.
Clinical Studies	2	Study 3 Open label, non-randomised, single centre, externally controlled trial to evaluate safety and efficacy of a single infusion of GSK2696274 in patients with Late Infantile (LI) and Early Juvenile (EJ) Metachromatic Leukodystrophy (MLD). Study 4 Open label, non-randomised, externally controlled trial to evaluate safety and efficacy of a single infusion of GSK2696274 in patients with Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD).
Extrapolation, Modeling & Simulation Studies	0	Not applicable.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes

Date of completion of the paediatric investigation plan:	31/01/2035
Deferral of one or more studies contained in the paediatric investigation plan:	Yes